{
    "clinical_study": {
        "@rank": "11743", 
        "arm_group": {
            "arm_group_label": "DESolve Novolimus Eluting Bioresorbable Coronary", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This prospective, consecutive enrolment, single-arm study will enroll up to 15 patients with\n      single de novo, Type A lesions < 10 mm in length and located in a native coronary artery\n      with a reference vessel diameter of 2.75 mm - 3.0 mm as measured by both offline QCA and\n      IVUS. All patients will receive a 3.0 x 14mm DESolve Stent loaded with approximately 40 mcg\n      of Myolimus.\n\n        -  Angiographic and intravascular ultrasound (IVUS) will be completed for all patients at\n           baseline and at 6 months.\n\n        -  Optical Coherence Tomography (OCT) will will be completed for all patients at baseline\n           and at 6 months.\n\n        -  Multi-slice computed tomography (MSCT) will be conducted on all patients enrolled at 12\n           and 24 months."
        }, 
        "brief_title": "Elixir Medical Clinical Evaluation of the DESolve Myolimus Eluting Bioresorbable Coronary Stent System - DESolve I Trial", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must be at least 18 years of age\n\n          -  Patient is able to verbally confirm understanding of risks, benefits and treatment\n             alternatives of receiving the DESolve Myolimus Eluting BCSS and he/she or his/her\n             legally authorized representative provides written informed consent, as approved by\n             the appropriate Ethics Committee of the respective clinical site, prior to any\n             clinical study related procedure\n\n          -  Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina,\n             silent ischemia, positive functional study electrocardiogram (ECG) changes consistent\n             with ischemia)\n\n          -  Patient must be an acceptable candidate for coronary artery bypass graft (CABG)\n             surgery\n\n          -  Patient must agree to undergo all clinical study required follow-up visits,\n             angiograms, IVUS, OCT and MSCT\n\n          -  Patient must agree not to participate in any other clinical study for a period of two\n             years following the index procedure\n\n        Exclusion Criteria:\n\n          -  Patients has a known diagnosis of acute myocardial infarction (AMI) within 72 hours\n             preceding the index procedure and CK and CK-MB have not returned within normal limits\n             at the time of procedure\n\n          -  The patient is currently experiencing clinical symptoms consistent with AMI\n\n          -  Patient has current unstable arrhythmias Patient has undergone previous percutaneous\n             interventions for lesions in either a non-target vessel or target vessel Patient has\n             undergone previous percutaneous interventions for lesions in either a non-target\n             vessel or target vessel\n\n          -  Patient has a known left ventricular ejection fraction (LVEF) < 30%\n\n          -  Patient has received a heart transplant or any other organ transplant or is on a\n             waiting list for any organ transplant\n\n          -  Patient is receiving or scheduled to receive chemotherapy for malignancy within 30\n             days prior to or after the procedure\n\n          -  Patient is receiving immunosuppression therapy and has known immunosuppressive or\n             autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus\n             etc.)\n\n          -  Patient is receiving or scheduled to receive chronic anticoagulation therapy (e.g.,\n             heparin, coumadin)\n\n          -  Patient has a known hypersensitivity or contraindication to aspirin, both heparin and\n             bivalirudin, both clopidogrel and ticlopidine, Myolimus, PLLA polymers or contrast\n             sensitivity that cannot be adequately pre-medicated\n\n          -  Elective surgery is planned within the first 6 months after the procedure that will\n             require discontinuing either aspirin or clopidogrel\n\n          -  Patient has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of <\n             3,000 cells/mm3, or documented or suspected liver disease.\n\n          -  Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5\n             mg/dL, or patient on dialysis)\n\n          -  Patient has a history of bleeding diathesis or coagulopathy or will refuse blood\n             transfusions\n\n          -  Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological\n             attack (TIA) within the past six months\n\n          -  Patient has had a significant GI or urinary bleed within the past six months\n\n          -  Patient has extensive peripheral vascular disease that precludes safe 7 French sheath\n             insertion\n\n          -  Patient has other medical illness (e.g., cancer or congestive heart failure) or known\n             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause\n             non-compliance with the clinical study plan, confound the data interpretation or is\n             associated with a limited life expectancy (i.e., less than one year)\n\n          -  Patient is already participating in another clinical study\n\n          -  Women of childbearing potential who have not undergone surgical sterilization or is\n             not post-menopausal (defined as amenorrheic for at least one year)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02086006", 
            "org_study_id": "ELX-CL-1002"
        }, 
        "intervention": {
            "arm_group_label": "DESolve Novolimus Eluting Bioresorbable Coronary", 
            "intervention_name": "DESolve Novolimus Eluting Bioresorbable Coronary Scaffold", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Coronary artery disease", 
        "lastchanged_date": "March 11, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Antwerp", 
                        "country": "Belgium", 
                        "zip": "2020"
                    }, 
                    "name": "AZ Middelheim Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "zip": "1023"
                    }, 
                    "name": "Auckland City Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "zip": "1023"
                    }, 
                    "name": "Mercy Angiography Unit"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "New Zealand"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolveTM MYOLIMUS ELUTING BIORESORBABLE CORONARY STENT SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS", 
        "overall_official": [
            {
                "affiliation": "Auckland City Hospital and Mercy Angiography Unit", 
                "last_name": "John Ormiston, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "ZNA Middelheim", 
                "last_name": "Stefan Verheye, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Institutional Review Board", 
                "Belgium: Ethics Committee", 
                "New Zealand: Health and Disability Ethics Committees"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Clinically-Indicated Major Adverse Cardiac Event (CI-MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Clinically-Indicated Target Lesion Failure (CI-TLF)", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Failure (CI-TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Revascularization (CI-TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Acute Success is classified according to the following definitions:\nProcedure success - Attainment of final result, < 50% residual stenosis of the target site, using the DESolve Myolimus Eluting BCSS device without the occurrence of in-hospital any Major Adverse Cardiac Endpoints.", 
                "measure": "Acute success - Procedure success", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Acute Success is classified according to the following definitions:\nDevice success - Attainment of final result, < 50% residual stenosis of the target site, using the study stent without the need for other non-study stents.", 
                "measure": "Acute success - Device success", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Clinically-Indicated Major Adverse Cardiac Event (CI-MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Clinically-Indicated Major Adverse Cardiac Event (CI-MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Clinically-Indicated Major Adverse Cardiac Event (CI-MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Clinically-Indicated Major Adverse Cardiac Event (CI-MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Clinically-Indicated Major Adverse Cardiac Event (CI-MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Clinically-Indicated Major Adverse Cardiac Event (CI-MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Lesion Failure (CI-TLF)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Clinically-Indicated Target Lesion Failure (CI-TLF)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Clinically-Indicated Target Lesion Failure (CI-TLF)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Lesion Failure (CI-TLF)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Lesion Failure (CI-TLF)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Lesion Failure (CI-TLF)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Failure (CI-TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Failure (CI-TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Failure (CI-TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Failure (CI-TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Failure (CI-TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Failure (CI-TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Revascularization (CI-TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Revascularization (CI-TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Revascularization (CI-TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Revascularization (CI-TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Revascularization (CI-TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Clinically-Indicated Target Vessel Revascularization (CI-TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02086006"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Elixir Medical Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Elixir Medical Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}